Open Access
Subscription Access
Open Access
Subscription Access
Transgenic Animals and Drug Development: a Review
Subscribe/Renew Journal
Pharmaceutical companies face the challenge that only ten percent of compounds tested in clinical trials eventually make it to the market and out of these, only a few will succeed to generate profit. Utilization of genetically altered animals (transgenic animals) in the pharmaceutical industry provides important insights into the function and interaction of particular gene products. Now, with the help of advanced technology numerous transgenic animals have been produced. The advent of transgenic animals has influenced the attrition rate in pharmaceutical research and development by increasing the quality of both targets and compounds. As with any experimental animal model, transgenic animals also have certain limitations but still they provide a powerful tool for the advancement of drugs in the pharmaceutical industry.
Keywords
Animals, Experiment, Drug
Subscription
Login to verify subscription
User
Font Size
Information
- Luthra PM, Singh J, Kumar R, Singh S. Role of Geneknockout Strategy in New drug Discovery. In: Kohli K, Gupta M, Tejwani S editors. Contemporary Perspectives on Clinical Pharmacotherapeutics. Elsevier, 2006:124-144.
- Paigen K, Eppig JT. A mouse phenome project. Mamm. Genome, 2000, 11: 715-717.
- Marks CL. Animal Models for Human Diseases: Is There a Future Without Them? The Journal of Nuclear Medicine Dec 2006, 47(12):50N-51N.
- Jaenisch R, Mintz B. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplatation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. USA 1974, 71:1250-1254.
- Palmiter RD, Brinster RL, Hammer RE, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982, 300:611-615.
- Palmiter RD, Norstedt G, Gelinas RE, Hammer RE, Brinster RL. Metallothionein-human GH fusion genes stimulate growth of mice. Science 1983, 222: 809-814.
- Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987; 51(3):503-512.
- Misra RP, Duncan SA. Gene targeting in the mouse. Endocrine Dec 2002.19(3):229-238.
- Gulezian D, Kram DJ, McCollough B, et al. Use of transgenic animals for carcinogenicity testing: Considerations and Impications for risk assessment. Toxicologic Pathology 2000; 28(3):482-499.
- Picciotto MR, Wickman K. Using knockout and transgenic mice to study neurophysiology and behaviour. Physiological Reviews Oct 1998;78(4):1131- 1155.
- Bowers BJ. Applications of transgenic and knockout mice in alcohol research. Alcohol research & Health 2000; 24(3):175-183.
- Lim KI, Dumenco LL, Yun J. et al. High level regulated expression of the chimeric P-enolpyruvate carboxykinase gene in transgenic mice. Cancer Res 1990; 50:1701-1708.
- Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad Sci.USA 1992; 89:5547- 5551.
- Sauer B, Henderson N. Site specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl Acad Sci. USA 1988; 85:5166-5170.
- Folkesson R, Winbald B, Benedikz E. Alzheimer transgenic models. Curr Opin Psychiatry 2002; 15:433- 439.
- Gupta SK. Drug Screening Methods 2004; Jaypee Publishers, New Delhi: 97-99.
- Deltour L et al. Journal of Biochemistry 1999; 274:16796-16801.
- Hodge CW, Mehmert KK, Kelley SP et al. Supersensitivity to allosteric GABAA receptor modulators and alcohol in mice lacking PKCå. Nature Neuroscience 1999;2:997-1002.
- Powell-Braxton L, Veniant M, Latvala RD et al. A mouse model of human familial hypercholesterolemia: markedly elevated LDL and severe atheroscelrosis on a low fat chow diet. Nat Med 1998; 4:934-938.
- Coleman DL. Obese and diabetes, two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14:141-148.
- Peterson RG, Shaw WN, Neel M-A et al. Zucker diabetic fatty rat as a model for noninsulin-dependent diabetes mellitus. ILAR News 1990; 32:16-19.
- Thurlby PL, Trayhurn P. The development of obesity in preweanling (ob/ob) mice. Br J Nutr 1978; 39:397-402.
- Crofford OB, Davis CK Jr. Growth characteristics, glucose tolerance and insulin sensitivity of New Zealand Obese mice. Metabolism 1965; 14:271-280.
- Ghosh MN. Fundamentals of experimental pharmacology 3rd edn. Hilton & Company publishers, Kolkata 2005:8-9.
- Mockrin SC, Dzau VJ, Gross KW, Horan MJ. Transgenic animals new approaches to hypertension research. Hypertension 1991; 17(3):394-399.
- Rudmann DG, Durham SK. Utilization of genetically altered animals in the Pharmaceutical industry. Toxicologic Pathology 1999; 27(1):111-114.
- Srinivasan K, Ramarao P. Animal models in type-2 diabetes research: An overview. Ind J Med Res, mar 2007; 125:451-472.
- Internet resource obtained from URL: http:// www.jax.org/resources/documents/imr/ 29. Internet resource obtained from URL: http:// tbase.jax.org.
Abstract Views: 295
PDF Views: 0